瑞士，星期五, 2020年2月28日 10:35PM 欧洲中部时间
Demiurge致力于利用AI为2019新型冠状病毒（COVID-19）筛选新型候选治疗药物。基于Demiurge开发的精确广谱病毒学模型，我们对已发表的COVID-19研究和临床数据进行了深入分析。
开发针对危重症患者的有效治疗方案至关重要，因为与SARS-CoV和MERS-CoV相比，COVID-19的危重症患者死亡率更高。
同样重要的是，针对危重症患者的有效治疗方案最好是基于价格低廉、供给广泛的成熟药物，使抗疫能力不同的国家都可以迅速有效地降低COVID-19危重症患者的死亡率。
我们特此正式宣布发现以下旨在降低COVID-19危重症患者死亡率的高效安全的新型候选治疗方案：
- 拓扑异构酶I型抑制剂（topoisomerase I inhibitors）和拓扑异构酶II型抑制剂（topoisomerase II inhibitors）的联合用药可能是一种非常有效的针对COVID-19危重症患者的新型候选治疗方案，可以保护危重症患者免于由COVID-19诱发的细胞因子风暴和其他并发症（包括院内感染和败血症）所导致的死亡。
- 已有体外细胞研究数据证实拓扑异构酶I型抑制剂能够抑制由病毒复制诱发的宿主免疫反应。也有体外细胞研究数据证实拓扑异构酶II型抑制剂可直接抑制病毒复制。
- 拓扑异构酶抑制剂联合疗法针对COVID-19的最佳用药顺序是先用拓扑异构酶I型抑制剂，然后再用拓扑异构酶II型抑制剂。因为拓扑异构酶I型抑制剂可减轻细胞因子风暴，继而协同促进拓扑异构酶II型抑制剂降低病毒产量。
- 拓扑异构酶I型抑制剂和拓扑异构酶II型抑制剂是已上市的成熟药物，并作为用于癌症治疗的有效且安全的化疗药物，已在全世界广泛使用了三十年以上。
- 伊立替康（irinotecan, 一种拓扑异构酶I型抑制剂）和依托泊苷（etoposide, 一种拓扑异构酶II型抑制剂）的组合疗法，做为多种肺癌的治疗方案，已经完成了相关的人类临床试验，并展示出了可靠的临床安全性。
- 伊立替康和依托泊苷的联合疗法可能是针对全球范围COVID-19危重症患者的特效候选治疗方案。因为伊立替康和依托泊苷不但已经在40多个国家普及，而且是世界卫生组织（WHO）基本药物清单中最安全有效的基本药物。
- 伊立替康和依托泊苷的联合疗法可能适合开展针对COVID-19危重症患者的超说明书用药（off-label use），因为目前尚无有效的针对COVID-19危重症患者的治疗方法。
在慢性病领域，药物专利的排他性和药物销售的独家性有效激励医药企业完成漫长而昂贵的新药开发，最终普惠大众。但是在流行病领域，时间是最为稀缺的要素。公众对治疗药物需求的紧迫性和药企对治疗药物供给的独家性通常在时间上是难以兼顾的。然而我们相信，在对抗流行病对生命的威胁时，深耕于医药事业的企业和个人都会将公众福祉放在首位。争分夺秒，阻击病毒。
因此，面对COVID-19, Demiurge决定第一时间向公众公布我们上述的进一步发现，放弃平常时期申请专利保护、独家权益合作等环节。以期能尽吾之所长，协同业界上下游，开展伊立替康和依托泊苷的联合疗法的超说明书用药。
关于Demiurge Technologies AG
Demiurge Technologies是一家以研究为基础的AI技术与生物医药公司，致力于将公开的海量生命科学数据转换为精确疾病模型。Demiurge创新地建立了利用全球医药三期临床试验结果预测的准确性来验证并改良精准疾病模型的科学进化闭环。同时Demiurge 致力于将精准疾病模型发现的创新药物进行商业化开发。 Demiurge于2016年开始运营，总部位于瑞士。
AI已成为一种新型强大的技术方法，它可以帮助人类更深入地了解疾病和更快地发现药物。但AI必须经过严格的测试，在公众的监督下证明其价值。Demiurge已经完成了90多个三期临床试验结果的预测，实现了大于80%的准确率。同时，我们在推特（Twitter）上邀请公众参与见证我们对正在进行中的全球新药三期临床试验结果的预测（@DemiurgeTech）。
因此，我们在这里基于AI提出的拓扑异构酶I型抑制剂和拓扑异构酶II型抑制剂的联合用药做为针对COVID-19危重症患者的新型候选治疗方案的科学假设，并公开邀请世界各地通过严谨设计的超说明书用药，验证伊立替康和依托泊苷的联合疗法是否能为COVID-19危重症患者带来临床受益。Demiurge敦促大众在任何相关临床数据公布之前，不应将任何拓扑异构酶I型抑制剂和拓扑异构酶II型抑制剂的联合用药做为等同于COVID-19的治疗药物擅自使用。
Disclaimers
This material is intended for information purposes only and is provided without any warranty of any kind, either expressed or implied. These statements are not guarantees of future performance, condition or results. Figures and graphs in this presentation are for illustration only and are may not match the actual scale. This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’,‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees. Demiurge Technologies AG (“Demiurge”) undertakes no duty or obligation to publicly update or revise the forward-looking statements or other information contained in this presentation. You should not view information related to the past performance of Demiurge and its affiliates or information about the market, as indicative of future results, the achievement of which cannot be assured. While some information used in this document may have been obtained from various published and unpublished sources considered to be reliable, Demiurge neither guarantees its accuracy or completeness nor accepts liability for any direct or consequential losses arising from its use. Amounts and percentages may reflect rounding adjustments and consequently totals may not appear to sum. None of the information in this presentation does, by itself, constitute an offering or an offering circular according to Article 652a of the Swiss Code of Obligations and is subject to change without notice. Any offer or solicitation with respect to any securities that may be issued by Demiurge will be made only by means of definitive offering memoranda or prospectus, which will be provided to prospective investors and will contain material information that is not set forth herein, including risk factors relating to any such investment. Before making an investment, you must obtain and carefully read all information needed to evaluate the investment, including, but not limited to the documents providing important disclosures regarding risks, fees and expenses. An investment in Demiurge may be volatile and can suffer from adverse or unexpected market moves or other adverse events. Investors may suffer the loss of their entire investment. An investment in Demiurge will be discrete from an investment in any funds or other investment programs managed by Demiurge and the results or performance of such other investment programs is not indicative of the results or performance that will be achieved by Demiurge or such investment programs.
* 中英文通告的最终解释以英文为准
